3 news items
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
GMAB
14 May 24
transformation (RT). All abstracts accepted for presentation have been published and may be accessed online via
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GMAB
3 Apr 24
/register/BI9da0549848d848cdaa4b6cd96079bafd. Registered participants will receive an email with a link to access dial-in information
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
ABBV
GMAB
27 Feb 24
-therapy-accelerated-approval-priority-review/priority-review. Accessed February 2024
- Prev
- 1
- Next